Targeted agent addition to herceptin has positive effect on metastatic HER-2 breast cancer, study finds
Friday, July 8, 2011 - 18:30
in Health & Medicine
Adding Afinitor to Herceptin, the main treatment for HER2-positive metastatic breast cancer, helps some women with disease that has been resistant to previous Herceptin-based therapies, according to a new study.